Helomics to Present at the Personalized Medicine World Conference 2016
Helomics Corporation, a privately-held comprehensive personalized healthcare company that provides comprehensive tumor profiling utilizing proprietary live cell and fixed cell products and services, announced today that the Company is scheduled to present at thePersonalized Medicine World Conference taking place in Silicon Valley on January 24-27, 2016.
Neil Campbell, President and Chief Executive Officer of Helomics, will provide an overview of the personalized healthcare landscape, the Company’s business and its comprehensive tumor profiling technologies during his presentation and will be available to participate in one-on-one meetings.
Event: Personalized Medicine World Conference
Date: Monday, January 25, 2016
Time: 2:30 p.m. (Pacific Time), Track 3
Location: Computer History Museum, Mountain View, CA
About the Personalized Medicine World Congress
The Personalized Medicine World Conference (PMWC) is an independent and established conference that attracts globally recognized authorities and experts across healthcare and biotechnology sectors. The Conference showcases practical content and disease pathways that help close the knowledge gap between different sectors, thereby catalyzing cross-functional collaboration to further adoption of personalized medicine in the clinic. For more information please visit: http://pmwcintl.com/index.php.
About Helomics™ Corporation
Helomics is a comprehensive personalized healthcare company, bringing the next generation of diagnostics to the oncology field. Helomics is dedicated to improving patient outcomes by providing a comprehensive personalized tumor profile utilizing a proprietary set of laboratory platforms that leverage both live and fixed cellular analysis to allow physicians to personally characterize malignant tumors. Helomics’ novel molecular and cellular markers and bioinformatics services are designed to support treatment decisions by providing vital information based on the specific biological processes of each individual’s cancer.
Helomics is headquartered in Pittsburgh, Pennsylvania where the company maintains two CLIA-certified laboratories. For more information please visit: www.helomics.com.
This release may contain forward-looking statements that involve risks and uncertainties. Market conditions and important factors that could cause actual results to differ materially from those communicated in any forward-looking statements information disclosed in presentations, conference calls or other public venues. We do not intend to update any forward-looking statements after the date of this press release.